Schwalbe Kathryn, Finelli Caitlin, Moon Soon, Niehaus Hannah, Kondajji Abhiram, Tu Chao, Fathalizadeh Alisan, Kroh Matthew, Allemang Matthew
Cleveland Clinic-South Pointe Hospital, 20000 Harvard Road, Warrensville Heights, OH, 44122, USA.
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
Surg Endosc. 2023 Feb;37(2):1384-1391. doi: 10.1007/s00464-022-09321-8. Epub 2022 May 24.
Gastroparesis is a life-altering diagnosis caused by the stomach's inability to function in the absence of a mechanical obstruction. The primary causes are idiopathic, diabetic, and postoperative. Our first-line treatment for medical refractory gastroparesis is the endoscopic per-oral pyloromyotomy (POP) procedure. Predicting clinical response cost effectively remains elusive.
All patients who underwent a POP procedure at our institution by a single surgical endoscopist from January 1, 2019 to June 30, 2020 were retrospectively reviewed. All endoscopic data were prospectively collected. The patients were followed by a survey including the Gastroparesis Cardinal Symptom Index (GCSI) and other relevant postoperative measures. The primary endpoint was clinical response defined as ≥ 1.0 decrease in the GCSI from preoperative to the time of survey. Secondary outcome was normalization of the gastric emptying study (GES).
Our patient population is 85% female and has an average age of 44.8 years. The diagnosis of gastroparesis is 71% iatrogenic, 19% postoperative, and 10% diabetic. On endoscopy, 30% had bile in the stomach and 65% had any degree of pylorospasm. The primary outcome measure of clinical response was 39% at an average of 697 ± 151 days post-POP, but 66% of patients attested to an improvement in their symptoms. Of 68 postoperative gastric emptying studies 50% normalized at an average of 145 ± 98 days. Following univariate and multivariate analyses of preoperative data and endoscopic findings, there were no significant predictors of clinical response. A preoperative GCSI ≥ 2.6 trends toward significance (OR 6.87, p = 0.058).
Endoscopic findings at the time of POP do not correlate with clinical response. The GCSI model currently used to measure clinical response may not accurately capture the full clinical picture. The long-term durability of endoscopic myotomy to treat medical refractory gastroparesis needs to be studied further to improve patient selection.
胃轻瘫是一种改变生活的诊断,由胃在无机械性梗阻的情况下无法正常运作引起。主要病因是特发性、糖尿病性和术后性。我们对药物难治性胃轻瘫的一线治疗方法是内镜下经口幽门肌切开术(POP)。有效地预测临床反应仍然难以实现。
回顾性分析了2019年1月1日至2020年6月30日期间在我们机构由一名外科内镜医师进行POP手术的所有患者。所有内镜数据均为前瞻性收集。通过包括胃轻瘫主要症状指数(GCSI)和其他相关术后指标的调查对患者进行随访。主要终点是临床反应,定义为从术前到调查时GCSI下降≥1.0。次要结果是胃排空研究(GES)恢复正常。
我们的患者群体中85%为女性,平均年龄为44.8岁。胃轻瘫的诊断中,71%为医源性,19%为术后性,10%为糖尿病性。在内镜检查中,30%的患者胃内有胆汁,65%的患者有任何程度的幽门痉挛。临床反应的主要结局指标在POP术后平均697±151天时为39%,但66%的患者证明其症状有所改善。在68项术后胃排空研究中,50%在平均145±98天时恢复正常。对术前数据和内镜检查结果进行单因素和多因素分析后,没有临床反应的显著预测因素。术前GCSI≥2.6有显著趋势(OR 6.87,p = 0.058)。
POP时的内镜检查结果与临床反应不相关。目前用于测量临床反应的GCSI模型可能无法准确反映全貌。内镜下肌切开术治疗药物难治性胃轻瘫的长期疗效需要进一步研究,以改善患者选择。